WO2013052995A3 - Improved developmental competence of oocytes - Google Patents

Improved developmental competence of oocytes Download PDF

Info

Publication number
WO2013052995A3
WO2013052995A3 PCT/AU2012/001219 AU2012001219W WO2013052995A3 WO 2013052995 A3 WO2013052995 A3 WO 2013052995A3 AU 2012001219 W AU2012001219 W AU 2012001219W WO 2013052995 A3 WO2013052995 A3 WO 2013052995A3
Authority
WO
WIPO (PCT)
Prior art keywords
oocytes
developmental competence
oocyte
improved developmental
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2012/001219
Other languages
French (fr)
Other versions
WO2013052995A2 (en
Inventor
Rebecca Louise ROBKER
Linda Linyan WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovation and Commercial Partners Pty Ltd
Original Assignee
Adelaide Research and Innovation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904259A external-priority patent/AU2011904259A0/en
Application filed by Adelaide Research and Innovation Pty Ltd filed Critical Adelaide Research and Innovation Pty Ltd
Publication of WO2013052995A2 publication Critical patent/WO2013052995A2/en
Anticipated expiration legal-status Critical
Publication of WO2013052995A3 publication Critical patent/WO2013052995A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/07—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure relates to a method of improving developmental competence of an oocyte. The method comprises exposing the oocyte and/or an embryo to an endoplasmic reticulum stress inhibitor and/or an inducer of heat shock proteins.
PCT/AU2012/001219 2011-10-10 2012-10-10 Improved developmental competence of oocytes Ceased WO2013052995A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011904259A AU2011904259A0 (en) 2011-10-10 Improved Developmental Competence of Oocytes
AU2011904259 2011-10-10

Publications (2)

Publication Number Publication Date
WO2013052995A2 WO2013052995A2 (en) 2013-04-18
WO2013052995A3 true WO2013052995A3 (en) 2014-09-25

Family

ID=48082598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2012/001219 Ceased WO2013052995A2 (en) 2011-10-10 2012-10-10 Improved developmental competence of oocytes

Country Status (1)

Country Link
WO (1) WO2013052995A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314167A (en) * 2019-07-04 2019-10-11 北京大学第三医院（北京大学第三临床医学院） Application and pharmaceutical preparation of the bile acid as preparation treatment PCOS drug

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018337761C1 (en) * 2017-09-22 2025-01-30 Adelaide university Methods and products for improving sperm quality
WO2019152625A1 (en) * 2018-01-31 2019-08-08 The Regents Of The University Of Colorado, A Body Corporate Markers of endoplasmic reticulum stress in ovarian follicular fluid predict ivf success
CN112155785A (en) * 2020-10-28 2021-01-01 内蒙古草原御驴科技牧业有限公司 Healthy breeding method for improving mating success rate of donkey mothers
CN113358876B (en) * 2021-04-27 2022-04-26 华南农业大学 Application of RPL26 protein in prediction of good response of crab eating monkey to superovulation
CN116457457B (en) * 2021-04-28 2024-03-01 山东大学 Method for improving early embryo development
CN113413384A (en) * 2021-05-24 2021-09-21 南京医科大学 Application of nicotinic acid in preparing medicine for treating and/or preventing fertility disorders of obese women
CN114917215B (en) * 2022-04-27 2024-01-23 中国科学院生物物理研究所 Use of active compounds in preventing or treating ovarian dysfunction diseases
CN117143809B (en) * 2023-10-30 2023-12-26 云南省畜牧兽医科学院 A method for improving the in vitro maturation quality of porcine oocytes
CN117582428A (en) * 2023-10-31 2024-02-23 广东省第二人民医院（广东省卫生应急医院） Application of saturated fatty acids and their derivatives in improving embryonic development quality

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HOTAMISLIGIL, G.S.: "Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease.", CELL, vol. 140, 2010, pages 900 - 917 *
PIRES ET AL.: "Anti-HSP90 autoantibodies in sera of infertile women identify a dominant, conserved epitope EP 6 (380-389 ) of HSP90 beta protein", REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, vol. 9, no. 16, 2011, pages 9 *
ROBKER, R. ET AL.: "Inflammatory pathways linking obesity and ovarian dysfunction", JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 88, 2011, pages 142 - 148, XP028193744, DOI: doi:10.1016/j.jri.2011.01.008 *
WU, L. ET AL.: "High-fat diet causes lipotoxicity Responses in cumulus-oocyte complexes and decreased ferilization rates", ENDOCRINOLOGY, vol. 151, no. 11, 2010, pages 5438 - 5445 *
WU, L. ET AL.: "Reduced Oocyte Quality and Poor Embryo Development Due to Dyslipidemia or Obesity Is Normalized By Blocking Endoplasmic Reticulum Stress", ENDOCR. REV., vol. 33, 2012 *
WU, L. ET AL.: "The impact of obesity on oocytes: evidence for lipotoxicity mechanisms", REPRODUCTION, FERTILITY AND DEVELOPMENT, vol. 24, 2011, pages 29 - 34 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314167A (en) * 2019-07-04 2019-10-11 北京大学第三医院（北京大学第三临床医学院） Application and pharmaceutical preparation of the bile acid as preparation treatment PCOS drug

Also Published As

Publication number Publication date
WO2013052995A2 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
WO2013052995A3 (en) Improved developmental competence of oocytes
IL273486A (en) A method for improving the removal of viruses by protein purification
PL2285816T5 (en) Method of isolation of nucleic acids
MX350121B (en) N-(3-carbamoylphenyl)-1h-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests.
EA201101306A1 (en) METHOD OF INCREASING THE OUTPUT OF POLYPEPTIDES
DK2584912T3 (en) Aqueous process for producing protein isolate and hydrolyzed protein from an oilseed product
CL2012000590A1 (en) Process to prepare w-transaminase (r) -selective.
IL228890A0 (en) Offset printing and the method of signaling coefficients for an adaptive sample offset
SMT201400142B (en) N- (1H-indazol-4-yl) immidazo [1,2-A] pyridin-3-carboxamide compounds substituted as cfms inhibitors
HUE058165T2 (en) Process for the production of proteins of plant origin
EP2672810A1 (en) Animal chew including interchangeable components
SI2464772T1 (en) Curable fiberglass binder comprising amine salt of inorganic acid
SI2464771T1 (en) Curable fiberglass binder comprising amine salt of inorganic acid
DK2598516T3 (en) Method of Protein Purification
DK2392548T3 (en) Process for the preparation of an amorphous silica composition and related amorphous silica-alumina composition
EA201590772A1 (en) A METHOD FOR INCREASING THE RESISTANCE TO ABIOTIC STRESS IN PLANTS USING CARBOXAMIDE DERIVATIVES OR THIOCARBOXAMIDE
BR112013006230C8 (en) process for the preparation of a substituted n-phenylhydroxylamine
BR112012002500A2 (en) PROCESS FOR THE PREPARATION OF ACID DERIVATIVES 1- (2-HALOBYPHENYL-4-YL) - CYCLOPROPANOCARBOXYLIC
DK2410872T3 (en) Process for the preparation of an animal feed
EA201070092A1 (en) ADAPTATION OF THE PITMAN MOORE STRAIN VIRUS VIRUS TO PRIMARY CELL CULTURE OF CHICKEN EMBRYOS FIBROBLASTES
KR100821648B9 (en) Unmanned automated repair method of pipelines
DK2451963T3 (en) METHOD OF INCREASING EXPRESSION PERFORMANCE PERFORMANCE OF VITAMIN-K-DEPENDENT PROTEINS
ATE543383T1 (en) METHOD FOR DELAYING THE RUITENING OF CROPS
FI20105300L (en) Method for separating embryo suspension risotto mass
CO6890113A2 (en) Methods for isolating substituted 4-chloro-2-fluoro-3-phenylboronic acids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12840171

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12840171

Country of ref document: EP

Kind code of ref document: A2